Current Issues of Pharmacy and Medical Sciences

Treatment of peritoneal metastases from gastric carcinoma

Curr Issues Pharm Med Sci., Vol. 30, No. 4, 173-179

Wojciech P. Polkowski, Karol Rawicz-Pruszynski, Jerzy Mielko,
Katarzyna Geca, Magdalena Skorzewska, Bogumila Cisel 

Department of Surgical Oncology, Medical University of Lublin, Staszica 11, 20-081 Lublin, Poland

DOI: 10.1515/cipms-2017-0032


Patients with advanced gastric cancer and positive peritoneal cytology and/or peritoneal dissemination are deemed to be incurable and to hold dismal prognosis. So far, the only treatment option for these patients has been palliative systemic (chemo)therapy. However, for the last three decades, great progress has been made in attempts to treat (potential) peritoneal dissemination by means of complete cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) after preoperative systemic therapy. This review is focused on the recent achievements of this multimodal strategy. Additionally, the review stands as background for the 4th International Conference “Advances in Surgical Oncology” that was held at the Medical University of Lublin (Poland) in November 2017, and dedicated to cytoreductive surgery and HIPEC for advanced gastric cancer.

Full text


gastric cancer, peritoneal metastases, gastrectomy, hyperthermic intraperitoneal chemotherapy, cytoreductive surgery


November 2019

Mon Tue Wed Thu Fri Sat Sun
        01 02 03
04 05 06 07 08 09 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30